Distinguished in Melanoma

Alexander Roesch

Zülpicher Str. 77, 
Koeln, NW, DE 
Distinguished in Melanoma
Zülpicher Str. 77, 
Koeln, NW, DE 
OverviewLocationsClinical Research

Overview

Alexander Roesch practices in Koeln, Germany. Mr. Roesch is rated as a Distinguished expert by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Lymphofollicular Hyperplasia, Actinic Keratosis, and Sebaceous Adenoma.

His clinical research consists of co-authoring 105 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 74 articles and participated in 1 clinical trial in the study of Melanoma.

Gender
Male

Locations

Zülpicher Str. 77, Koeln, NW 50937, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Biopsy- and Biology-driven Optimization of Targeted Therapy of Metastatic Melanoma in BRAF Inhibitor Non-pretreated and Pretreated Subjects With Advanced, Non-resectable (STAGE IIIC) or Metastatic (StAGE IV) BRAF Mutation-positive Melanoma
Biopsy- and Biology-driven Optimization of Targeted Therapy of Metastatic Melanoma in BRAF Inhibitor Non-pretreated and Pretreated Subjects With Advanced, Non-resectable (STAGE IIIC) or Metastatic (StAGE IV) BRAF Mutation-positive Melanoma
Enrollment Status: Terminated
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 2

105 Total Publications

Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 2023, 15, 3448.
Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 2023, 15, 3448.
Journal: Cancers
Published: September 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Roesch's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile